Press Releases

VALENCIA, Calif., Sept. 18 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the UBS Global Life Sciences Conference on September 25, 2007 at 10:30 AM ET at the Grand Hyatt Hotel in New York, NY.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

SOURCE MannKind Corporation

CONTACT:
Dick Anderson,
Chief Financial Officer
of MannKind Corporation,
+1-661-775-5302,
danderson@mannkindcorp.com;
or
Investor Relations,
Evan Smith
of Financial Dynamics,
+1-212-850-5606,
mnkd@fd.com,
for MannKind Corporation

Web site: http://www.mannkindcorp.com